Skip to main content
Clinical Trials/NL-OMON47575
NL-OMON47575CompletedPhase 2

Treatment of central sleep apnoea and Cheyne Stokes respiration in patients with heart failure: <br>nasal high-flow oxygen therapy?<br> - Nasal high flow in heart failure patients with CSAS

niversitair Medisch Centrum Groningen0 sites10 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 64 (—)

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Moderate to severe central sleep apnoea (CSA)/Cheyne Stokes respiration (apnoea/hypopnoea index>15), in which CSA is defined when at least 50% of the apnoea*s are central apnoea*s
  • Heart failure diagnosed by cardiologist

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Other diseases affecting respiration during sleep (COPD GOLD 3 or 4, neuromuscular disorders, thorax cage deformities)
  • At the moment of the inclusion, the patient does not have a therapy to treat the CSA, such as CPAP, oxygen, BiPAP or acetazolamide.

Investigators

Similar Trials